Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here?

Drug Safety Sciences and the Bottleneck in Drug Development

(2011) P B Watkins   CLINICAL PHARMACOLOGY & THERAPEUTICS

Genetic association studies in drug-induced liver injury

(2011) Ann K. Daly et al.   DRUG METABOLISM REVIEWS

Susceptibility to Amoxicillin-Clavulanate-Induced Liver Injury Is Influenced by Multiple HLA Class I and II Alleles

(2011) M. Isabel Lucena et al.   GASTROENTEROLOGY

HLA-DQA1*02:01 Is a Major Risk Factor for Lapatinib-Induced Hepatotoxicity in Women With Advanced Breast Cancer

(2011) Colin F. Spraggs et al.   JOURNAL OF CLINICAL ONCOLOGY

Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells

(2010) S. Tamir Rashid et al.   JOURNAL OF CLINICAL INVESTIGATION

A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury

(2010) Jonathan B Singer et al.   NATURE GENETICS

Drug-induced liver injury: past, present and future

(2010) Ann K Daly   PHARMACOGENOMICS

Drug-Induced Liver Injury Network (DILIN) Prospective Study

(2009) Robert J. Fontana et al.   DRUG SAFETY

HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin

(2009) Ann K Daly et al.   NATURE GENETICS

Fulfilling the Promise of Personalized Medicine? Systematic Review and Field Synopsis of Pharmacogenetic Studies

(2009) Michael V. Holmes et al.   PLoS One